Pancreatectomy; Hyperglycemia Clinical Trial
Official title:
Separate and Combined Extrapancreatic Effects of Glucose-dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1
The two gut-derived hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) is secreted from intestinal cells in relation to a meal and increase insulin secretion from the pancreas. The hormones also exert effects outside the pancreas, but especially for GIP, these are poorly investigated. Because of this, only GLP-1 based drugs (GLP-1 receptor agonists) are on the market for the treatment of type 2 diabetes and obesity. Nonetheless, a new drug is in clinical development: a combined GIP-GLP-1-receptor agonist (tirzepatide), which has shown better results than GLP-1 alone. The mechanism behind these impressive effects are unknown and in this study, the investigators will look into the exptrapancreatic effects of GIP and GLP-1, separate and combined and thus elucidate the mechanisms of action of this new drug class.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04409171 -
Glucose Metabolism After Partial Pancreatectomy
|
||
| Not yet recruiting |
NCT04038931 -
Collection of Human Liver Biopsy and Whole Blood Samples From T1DM, TP or PP Patients for Potential Use for Insulin Producing Cells in Future Clinical Studies
|
||
| Active, not recruiting |
NCT03260387 -
A Prospective Observational Study of TPIAT
|
||
| Active, not recruiting |
NCT03978702 -
Evaluation of the Impact of Pancreatectomy on Systemic Immunity
|
N/A | |
| Completed |
NCT03174353 -
A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula
|
Phase 2 | |
| Completed |
NCT03303196 -
Bionic Pancreas in Children With Hyperinsulinism and Post-Pancreatectomy Diabetes
|
N/A |